170 Poisoning
Overview of Approaches for Evaluation and Treatment
Gastrointestinal Decontamination
The theory of gastric decontamination (GID) is that removal of toxins from the stomach (where absorption is poor) before they move into the small bowel (where absorption is more rapid) decreases the toxicity of the poisoning. Because of controversies regarding the role of gut decontamination, senior toxicologists from the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists (EAPCCT) agreed to collaborate on the production of Position Statements on GID treatments. These statements, published in 1997, are systematically developed guidelines founded on a criteria-based critical review of all relevant scientific literature.1 The Position Statements were updated in 2004. GID Position Statement summaries are presented in this chapter.
Ipecac
Ipecac is a prepared form of the Cephaelis acuminata or Cephaelis ipecacuanha plants. Vomiting within 30 minutes after administration is caused by local irritation of the gastric mucosa. Vomiting after 30 minutes is centrally induced.2
Position Statement
Syrup of ipecac should not be administered routinely for the management of poisoned patients. In experimental studies, the amount of marker removed by ipecac treatment was highly variable and diminished with time. There is no evidence from clinical studies that ipecac improves outcome for poisoned patients, and its routine administration should be abandoned.3
Gastric Lavage
For gastric lavage, a large-bore (36F-40F) orogastric tube is passed, after which small volumes (200-300 mL) of liquid are alternately administered and aspirated. Endotracheal intubation should precede this procedure in comatose patients. An oral airway prevents biting of the tube. The amount of stomach contents removed via this procedure is highly variable and decreases with time.4–6 The procedure can actually push stomach contents into the intestine.7 Contraindications include loss of protective airway reflexes (unless the patient is endotracheally intubated), ingestion of a corrosive substance or a hydrocarbon, gastrointestinal pathology, and other medical conditions that could be worsened by the use of lavage. Complications of the procedure include aspiration, laryngospasm, hypoxia, hypercapnia, mechanical injury, and fluid and electrolyte imbalances in children.8
Position Statement
Gastric lavage should not be employed routinely in the management of poisoned patients. It should not be considered unless the patient has ingested a potentially life-threatening amount of a poison and the procedure can be undertaken within 60 minutes after ingestion. Even then, clinical benefit has not been confirmed in controlled studies.8
Single-Dose Activated Charcoal
Activated charcoal is made when coconut shells, peat, wood, or other materials undergo controlled pyrolysis and are subsequently activated by heating in steam or air at high temperatures. Activation creates multiple internal pores and the small particle size necessary for adsorption. The particles have a large surface area and are capable of adsorbing poisons with varying affinities. Although in vitro studies demonstrate adsorption of many drugs to activated charcoal, animal studies reveal variable reductions in the systemic uptake of marker substances.9 Volunteer and clinical studies have not demonstrated that single-dose administration of activated charcoal improves outcome. Contraindications to the administration of activated charcoal include decreased level of consciousness and unprotected airway, ingestion of caustic substances or hydrocarbons, gastrointestinal pathology, and medical conditions that could be further compromised by the administration of activated charcoal. Complications include aspiration and direct administration of charcoal into the lung.10
Because activated charcoal is an inert substance, it is thought that lung injury after aspiration of activated charcoal is caused by gastric contents. Aspiration of gastric contents causes neutrophils to release neutrophil elastase, which increases pulmonary vascular permeability.11 In comparison, intratracheal administration of activated charcoal does not increase elastase in the bronchoalveolar fluid.12 Activated charcoal can activate alveolar macrophages, which are a potent source of oxygen radicals, proteases, and other inflammatory mediators. Charcoal also causes obstruction of small distal airways Overdistention of alveolar segments in areas not occluded by charcoal leads to volutrauma in those areas, which increases microvascular permeability.13 Although case reports reveal long-term pulmonary pathology after aspiration or instillation of activated charcoal,14,15 the true incidence of chronic problems after charcoal aspiration is unknown.
Position Statement
Single-dose activated charcoal should not be administered routinely in the management of poisoned patients. The effectiveness of charcoal decreases with time; the greatest benefit is obtained within the first hour after ingestion. Administration of activated charcoal may be considered if a patient has ingested a potentially toxic amount of poison (that is known to be adsorbed to charcoal) not longer than 1 hour before treatment. There is no evidence that the administration of activated charcoal improves outcome.10,16
Whole-Bowel Irrigation
Whole-bowel irrigation consists of administration through a nasogastric tube of an osmotically balanced, polyethylene glycol–based electrolyte solution to decontaminate the entire gastrointestinal tract by physically expelling intraluminal contents. As much as 1500 to 2000 mL/h can be administered to an awake patient. Negotiations to let the patient attempt to drink the solution only cause delay, because patients are unable to drink at a constant rate. Contraindications include bowel pathology, unprotected or compromised airway, hemodynamic instability, and intractable vomiting. Complications are nausea, vomiting, and abdominal cramps.18
Position Statement
Whole-bowel irrigation should not be used routinely in the poisoned patient. Whole-bowel irrigation should be considered for potentially toxic ingestions of sustained-release or enteric-coated drugs. There are insufficient data to support or exclude the use of whole-bowel irrigation for toxic ingestions of lithium, iron, lead, zinc, or packets of illicit drugs.18
Enhanced Elimination
Multiple-Dose Activated Charcoal
Multiple-dose activated charcoal is the repeated oral administration of activated charcoal to enhance drug elimination. If the drug concentration in the gut is lower than that in the blood, the drug will passively diffuse back into the gut. The concentration gradient, intestinal surface area, permeability, and blood flow determine the degree of passive diffusion. As the drug passes continuously into the gut, it is adsorbed onto the charcoal particles, a process called gastrointestinal dialysis. Multiple-dose activated charcoal also interrupts the enterohepatic and enterogastric circulation of drugs. Drugs with a prolonged elimination half-life, a small volume of distribution (less than 1 L/kg), and little protein binding are the most amenable to this sort of management.19
The initial dose of charcoal is 50 to 100 g, and this treatment is followed every 1, 2, or 4 hours by a dose equivalent to 12.5 g/h. More frequent, smaller doses may prevent vomiting. Addition of a cathartic (e.g., sorbitol) can be considered for the initial one or two doses. Continuous use of a cathartic can cause diarrhea and fluid and electrolyte imbalances. Multiple-dose activated charcoal can be continued until the patient improves clinically. Contraindications include an unprotected airway, intestinal obstruction, and an anatomically abnormal gastrointestinal tract. Complications include bowel obstruction and vomiting with subsequent aspiration.19
Position Statement
Multiple-dose activated charcoal should be considered if a patient has ingested a life-threatening amount of carbamazepine, dapsone, phenobarbital, quinine, or theophylline. With all of these drugs, data confirm enhanced elimination, although no controlled studies have demonstrated clinical benefit.19
Urinary Alkalinization
Urinary alkalinization is the administration of intravenous (IV) sodium bicarbonate to produce urine with a pH ≥ 7.5. The objective of treatment is pH manipulation, not forced diuresis. Hypokalemia is the most common complication. Alkalemia also can occur.20
Position Statement
Urinary alkalinization should be considered as first-line treatment in patients with moderately severe salicylate poisoning who do not meet the criteria for hemodialysis. Urinary alkalinization also should be considered for patients with severe poisoning due to 2,4-dichlorophenoxyacetic acid or mecoprop (MCPP) poisoning. Urinary alkalinization is not recommended as first-line treatment for cases of phenobarbital poisoning, because multiple-dose activated charcoal is superior.20